Fetal therapy of LUTO (lower urinary tract obstruction) - a follow-up observational study

• Published in: The journal of maternal-fetal & neonatal medicine Vol. 35; no. 25; pp. 8536 - 8543
• Main Authors: Keil, Corinna, Bedei, Ivonne, Sommer, Lara, Koemhoff, Martin, Axt-Fliedner, Roland, Köhler, Siegmund, Weber, Stefanie
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 12-12-2022
• Subjects: LUTO; megacystis; prenatal therapy; renal prognosis; vesicoamniotic shunting; megacystis; renal prognosis; vesicoamniotic shunting; prenatal therapy; LUTO
• ISSN: 1476-7058; 1476-4954
• DOI: 10.1080/14767058.2021.1988562

Fetal megacystis (MC) can be severe and is mainly caused by fetal lower urinary tract obstruction (LUTO). Mortality of fetal LUTO can be high as a result of pulmonary hypoplasia and/or (chronic) renal insufficiency. Several technical procedures for vesicoamniotic shunting (VAS) were developed to improve fetal MC outcomes.
We present the outcome of nine fetuses with MC who received VAS in the prenatal period (14 + 6 to 27 + 6 weeks GA) using the Somatex
®
intrauterine shunt system. MC was defined as an increased longitudinal measurement of the bladder >15 mm. The median follow-up time after birth was 18 months.
Eight Fetuses had uncomplicated VAS intervention. One case developed PPROM 24 h after VAS leading to abortion. Pregnancy was later terminated in further two cases. All six live-born infants received intensive care treatment. Invasive-mechanical ventilation was necessary in one case who died 24 h post-partum of severe cardiac depression. Five infants who survived the follow-up time developed chronic renal insufficiency (CRI), with one infant developing end-stage renal failure requiring peritoneal dialysis.
Overall, 5 of 9 LUTO fetuses (55%) undergoing VAS with the Somatex
®
intrauterine shunt system showed long-term survival beyond the neonatal period of 28 d (5/9; 55%) with varying morbidity.